Home » Business News » 2013 » March » March 11, 2013

Hemoglobin A1c Testing Market to Spike to $1.6 Billion by 2017

March 11, 2013 - NEW YORK, NY cites in its newly published "Hemoglobin A1c Testing Markets" report that the hemoglobin A1c testing market will spike to $1.6 billion by 2017. For more information, visit:

Hemoglobin A1c testing can be categorized into three main modalities: clinical laboratory HbA1c testing, point of care HbA1c testing and physician office laboratories (POL) HbA1c testing. The POC segment occupies nearly one third of the total hemoglobin A1c testing market and is one of the fastest growing areas, with a CAGR of 12.7% between 2012 and 2017. The U.S. hemoglobin A1c testing market is projected to grow to $518 million in 2017. Combined, the developed regions comprise greater than 75% of the total hemoglobin A1c testing market.

The "Hemoglobin A1c Testing Markets" report covers:

  • Diabetes
  • Pre-Diabetes Syndrome
  • Metabolic Syndrome
  • High-Performance Liquid Chromatography (HPLC)
  • Immunoassays
  • Boronate Affinity Chromatography
  • Enzymatic Assay
  • Micro-Optical Detection Methods
  • Diabetes Control and Complications Trial (DCCT)
  • National Glycohemoglobin Standardization Program (NGSP)
  • International Federation of Clinical Chemistry (IFCC)
  • A1c Derived Average Glucose (ADAG)

The "Hemoglobin A1c Testing Markets" report examines companies manufacturing hemoglobin A1c testing equipment and supplies in the world. Companies covered include: A. Menarini, Abbott, Alere, Arkray, Axis-Shield, Bayer Healthcare, Beckman Coulter, Bio-Rad, EKF, Infopia, Ortho Clinical, Quotient, Randox, Roche, Siemens, Tosoh and Trinity.

Detailed charts with sales forecasts and marketshare data are included. For more information, visit:

About is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit

Important Notice

The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.

Add to Digg Bookmark with Add to Newsvine

Media Relations


Comment on this story